Case Report: Hypothalamic Amenorrhea Following COVID-19 Infection and Review of Literatures

Paolo Facondo1, Virginia Maltese1, Andrea Delbarba1, Ilenia Pirola1, Mario Rotondi2, Alberto Ferlin3 and Carlo Cappelli1*

1 Department of Clinical and Experimental Sciences, Endocrine and Metabolic Unit, University of Brescia, Azienda Socio Sanitaria Territoriale (ASST) Spedali Civili Brescia, Brescia, Italy, 2 Unit of Internal Medicine and Endocrinology, Istituto Clinico Scientifico (ICS) Maugeri Istituto di Ricovero e Cura a Carattere Scientifico (I.R.C.C.S.), Laboratory for Endocrine Disruptors, University of Pavia, Pavia, Italy, 3 Unit of Andrology and Reproductive Medicine, Department of Medicine, University of Padova, Padova, Italy

SARS-CoV-2 infection, responsible for the coronavirus disease 2019 (COVID-19), can impair any organ system including endocrine glands. However, hypothalamic–pituitary dysfunctions following SARS-CoV-2 infection remain largely unexplored. We described a case of hypothalamic amenorrhea following SARS-CoV-2 infection in a 36-year-old healthy woman. The diagnostic workup excluded all the causes of secondary amenorrhea, in agreement to the current guidelines, whereas the gonadotropin increase in response to GnRH analogue tests was suggestive for hypothalamic impairment. Therefore, since our patient did not present any organic cause of hypothalamic–pituitary disorder, we hypothesized that her hypothalamic deficiency may have been a consequence of SARS-CoV-2 infection. This assumption, besides on the temporal consecutive, is strengthened by the fact that SARS-CoV-2 infection can impair the hypothalamic circuits, altering the endocrine axes, given that angiotensin-converting enzyme 2 receptors have also been observed in the hypothalamus. We reviewed the literature regarding hypothalamic–pituitary dysfunction in patients with SARS-CoV-2 infection. No study has previously described female hypogonadotropic hypogonadism with secondary amenorrhea following COVID-19. We suggest clinicians focusing greater attention on this possible endocrine disorder.

Keywords: hypothalamic amenorrhea, COVID-19, hypothalamic–pituitary dysfunction, female hypogonadotropic hypogonadism, central amenorrhea

INTRODUCTION

Coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a primarily respiratory system disease, but it can lead to systemic manifestations, including in the cardiovascular, neurological, and gastrointestinal systems (1). Moreover, COVID-19 can also affect the endocrine system, since the angiotensin-converting enzyme 2 (ACE2) receptor—which is responsible together with transmembrane serine protease 2 (TMPRSS2) for the entry of SARS-CoV-2 to the cells—is also expressed in endocrine glands (thyroid, testis, ovary, adrenal, and pituitary) (2, 3). In addition, this...
virus can impair the hypothalamic circuits, altering the endocrine axes, since ACE2 receptors have also been observed in the hypothalamus (4). However, the endocrine complications, especially hypothalamic–pituitary dysfunction of COVID-19, are poorly reported and remain largely unexplored (5).

**Hypothalamic–Pituitary Dysfunction Following COVID-19: Review of Literatures**

We present a case of hypothalamic amenorrhea following SARS-CoV-2 infection, and we reviewed the literature regarding hypothalamic–pituitary dysfunction of COVID-19 to evaluate if this possible dysfunction has already been reported.

Hypothalamic–pituitary dysfunctions following SARS-CoV-2 infection in adults have been described (Table 1) (6–29).

The most frequently reported hypothalamic–pituitary alterations following COVID-19 are pituitary apoplexy and the syndrome of inappropriate antidiuretic hormone secretion (SIADH) (5, 30).

Pituitary apoplexy is an acute syndrome due to a sudden vascular damage of the pituitary gland, with hemorrhagic infarction and ischemia, mainly in the context of a preexisting pituitary macroadenoma. Frara et al. have well described patients with pituitary diseases in which COVID-19 caused pituitary apoplexy, as a plausible precipitating risk factor (30). Moreover, Gaudino et al. recently reported hypothalamic–pituitary failure also in a child with SARS-CoV-2 infection and suprasellar tumor (31).

Table 1 describes the clinical features and outcomes of cases of pituitary apoplexy in patients with SARS-CoV-2 infection.

On the other end, SIADH in COVID-19 seems due to several mechanisms related to systemic inflammation and pulmonary infection (17). In particular, a marked elevation of inflammatory cytokines can result in SIADH via two mechanisms. First, inflammatory cytokines (such as IL-6) can directly stimulate the no osmotic release of antidiuretic hormone (ADH) (32). Second, these cytokines can injure the lung tissue and alveolar cells, inducing SIADH via the hypoxic pulmonary vasoconstriction pathway (33).

In patients with COVID-19, SIADH generally occurs with signs of moderate-severe hyponatremia (Table 1).

Few cases of central diabetes insipidus, central hypocortisolism, and rare findings of neurological symptoms with suspected radiological evidence of hypothalamic involvement have been described in patients with SARS-CoV-2 infection (Table 1).

**Case Report**

A 36-year-old woman came for evaluation at the Department of Clinical and Experimental Sciences, Endocrine and Metabolic Unit, ASST Spedali Civili Brescia, University of Brescia (Italy) in September 2021, reporting secondary amenorrhea for 6 months (last menstruation in March 8, 2021). Prior to March 2021, she reported regular menstrual cycles, one physiological pregnancy (in 2012), and no comorbidities or long-term therapy, and blood exams showed eugonadism (last assessment in December 2019). In March 2021, the patient presented symptoms including slight fever, myalgias, fatigue, sore throat, and hyposmia and was diagnosed with SARS-CoV-2 infection by nasopharyngeal reverse transcriptase polymerase reaction (positive swab on March 15, 2021). These symptoms were spontaneously resolved in 12 days without treatment or hospitalization (negative swab on April 15, 2021). She was vaccinated against SARS-CoV-2 in September 2021.

In July 2021, the patient underwent a gynecological evaluation: physical examination and pelvic ultrasound were normal, she presented no clinical and biochemical signs of hyperandrogenism (normal values of adrenal androgens), blood exams suggested hypogonadotropic hypogonadism (Table 2), and the medroxyprogesterone acetate (MAP) test was negative; pregnancy, polycystic ovary syndrome (PCOS), and gynecological causes of amenorrhea were excluded.

In August 2021, she underwent a dynamic enhanced MRI of the brain and pituitary region (given the finding of hypogonadotropic hypogonadism), showing a normal appearance of the sella turcica and regular dimensions of the adenohypophysis with uncertain millimetric (3 mm) pituitary microadenoma, and a normal appearance of the neurohypophysis, pituitary peduncle, median line structures, cavernous sinuses, optic chiasm, and supra- and subtentorial brain parenchyma. The FLAIR and DWI diffusive sequences of brain imaging did not report hypothalamic or other anormal findings.

At our endocrinological evaluation (September 2021), her temperature was 35.8°C, her pulse measured 72 beats per minute, and her blood pressure was 114/72 mmHg, weight 51 kg, height 1.58 m, and body mass index (BMI) 20.5 kg/m². She had no significant medical history, had no long-term therapy (no contraceptive pill or other drugs), and had never smoked. Besides amenorrhea, she presented no symptoms. Physical examination was normal. She reported no excessive physical training or significant fluctuations in body weight in recent years. The patient’s psychological state was carefully evaluated with particular care for stress related to the infection. The patient excluded any psychosocial state of stress.

On the suspicion of central amenorrhea, we carried out several blood tests (performed in the laboratory at our medical center): we excluded systemic disease (normal levels of inflammatory, coagulation, and hepatic markers), hemochromatosis (normal values of iron, ferritin, and transferrin saturation), celiac disease (negative anti-gliadin and anti-transglutaminase antibodies and no symptoms), overt primary thyroid disease, pituitary hypersecretion, adrenal axis deficit, and hyperprolactinemia, while we found low fT4 (free thyroxine) and confirmed hypogonadotropic hypogonadism, characterized in particular by low LH (luteinizing hormone) and estradiol with normal FSH (follicle-stimulating hormone) levels (Table 2).

Then, on the suspicion of central amenorrhea and possible central hypothyroidism, we performed a TRH test (intravenous infusion of 200 mcg thyrotropin-stimulating hormone) and a GnRH (gonadotropin-releasing hormone) analogue test (with subcutaneous triptorelin 0.1 mcg), on September 30, 2021, and October 7, 2021, respectively. These tests indicated a delayed pituitary response to TRH and a gonadotropin increase to the GnRH analogue, suggesting a hypothalamic deficiency (Tables 3 and 4). In particular, LH and FSH were suppressed and normal, respectively, at baseline and both normally increased acutely and after 24 h from triptorelin injection. Seven days after the TRH test, she presented euthyroidism with normal values of TSH (thyrotropin-stimulating hormone), fT4, and fT3 (free thyroxine).
| Type of hypothalamic–pituitary dysfunction (with number of cases reported) | Case patient (M/F, yr, condition/comorbidities) | Time to onset of dysfunction after COVID-19 infection | Clinical presentation of hypothalamic–pituitary dysfunction | Outcome | Reference |
|---|---|---|---|---|---|
| Pituitary apoplexy (12 cases) | F, 28 yr, third trimester pregnant | Contextual to the infection | Headache, visual alterations, at pituitary imaging cystic-solid lesion with expanded sella and hemorrhage (suspected within a pregnancy enlargement of pituitary, doubtful preexisting adenoma) | TNS surgery after partum, with consequence of central hypothyroidism and central hypogonadism | Chan et al. (6) |
|  | F, 44 yr, healthy | 6 days | Headache, visual alterations, at pituitary imaging cystic-solid lesion with expanded sella and hemorrhage (suspected within a preexisting adenoma) | Refused surgery, central hypothyroidism | Ghosh et al. (7) |
|  | F, 65 yr, healthy | Acute presentation | Headache, at pituitary imaging recognition of hemorrhagic pituitary microadenoma with signs of pituitary apoplexy | Hydrocortisone treatment, central hypothyroidism | Bordes et al. (8) |
|  | M, 35 yr, healthy | 2–3 weeks | Headache, at pituitary imaging recognition of hemorrhagic pituitary macroadenoma with signs of pituitary apoplexy | TNS surgery, without complications | Santos et al. (9) |
|  | M, 46 yr, healthy | Acute presentation | Headache, at pituitary imaging recognition of hemorrhagic lesion and neuro-ophthalmic involvement | Corticosteroid therapy and discharge | Katti et al. (11) |
|  | M, 27 yr, pre-existing Non-secreting pituitary macroadenoma | Acute presentation | Headache, visual alterations, at pituitary imaging cystic-solid lesion with expanded sella and hemorrhage in the context of a preexisting macroadenoma | Death for pulmonary complications | Solorio-Pineda et al. (12) |
|  | M, 55 yr, T2DM, hypertension and pituitary macroadenoma resection 11 years ago, hormonal replacement therapy for panhypopituitarism | Acute presentation | Progressive decrease in visual acuity and oculomotor nerve palsy, at pituitary imaging enlarging residual pituitary adenoma with signs of pituitary apoplexy | TNS surgery, death for pulmonary complications | Kamel et al. (13) |
|  | M, 75 yr, gastrointestinal disease | 1 month | Headache, at pituitary imaging pituitary macroadenoma (previously undiagnosed) with signs of pituitary apoplexy | Hydrocortisone and thyroid replacement treatment, discharged in endocrinologic follow-up, follow-up pituitary imaging showed reduction in the size of the hemorrhagic lesion | Liew et al. (14) |
|  | 3 cases | Few days | Headache, visual alterations and/or nerve palsies, at pituitary imaging cystic-solid lesion with expanded sella and hemorrhage (suspected within a preexisting adenoma, confirmed after surgery) | TNS surgery, with complete symptoms resolution and without complications; substitutive treatment with hydrocortisone and levotyroxine, and in the first patient also desmopressin; in the third patient consequence of central hypogonadism non yet treated | Martinez-Perez et al. (15) |
| SIADH (10 cases) | F, 70 yr, hypertension | Contextual to the infection | Signs of moderate-severe hyponatremia | Treatment of hyponatremia with clinical resolution | Uddin Chowdhury et al. (16) |
|  | 3 cases | Contextual to the infection | Signs of moderate-severe hyponatremia | Treatment of hyponatremia with clinical resolution | Youasf et al. (17) |
|  | M, 58 yr, hypertension, asthma and dyslipidemia; M, 20 yr, healthy; M, 47 yr, healthy | Contextual to the infection | Signs of moderate-severe hyponatremia | Treatment of hyponatremia with clinical resolution | Ravioli et al. (18) |
|  | 2 cases | Contextual to the infection | Signs of moderate-severe hyponatremia | Treatment of hyponatremia with clinical resolution | Sheikh et al. (19) |
|  | F, 80 yr, healthy; M, 62 yr, healthy | Contextual to the infection | Signs of moderate-severe hyponatremia | Treatment of hyponatremia with clinical resolution | (Continued) |
| Type of hypothalamic–pituitary dysfunction (with number of cases reported) | Case patient (M/F, yr, condition/comorbidities) | Time to onset of dysfunction after COVID-19 infection | Clinical presentation of hypothalamic–pituitary dysfunction | Outcome | Reference |
|---|---|---|---|---|---|
| Central diabetes insipidus (with also central adrenal insufficiency in one case) (3 cases) | M. 66 yr, T2DM, hypertension, hypothyroidism, and coronary insufficiency | Contextual to the infection | Signs of moderate-severe hyponatremia | Treatment of hyponatremia with symptoms resolution; hyponatremia persisted throughout follow-up and resolved spontaneously after 2 months | Saad et al. (20) |
| | M. 59 yr, healthy | Contextual to the infection | Hyponatremia with presyncope and sinus bradycardia | Treatment of hyponatremia with clinical resolution | Amir et al. (21) |
| | M. 75 yr, healthy | Likely contextual to the infection | Signs of hyponatremia with tonic-clonic seizures | Treatment of hyponatremia with clinical resolution | Ho et al. (22) |
| | F. 60 yr, healthy | Eight weeks after COVID-19 infection | Polyuria, nocturia, polydipsia, craving for cold water, and hyponatremia; serum and urine osmolarity suggestive for diabetes insipidus; at brain imaging signs of infundibuloneurohypophysitis | Oral desmopressin 0.1 µg twice a day, with resolution of symptoms | Misgar et al. (23) |
| Central hypocortisolism (2 cases, with also Sheikh et al. (25)) | M. 47 yr, T2DM | 1 week | Biochemical exams suggestive for central hypocortisolism (with dyspepsia and eosinophilia) | Hydrocortisone treatment with clinical resolution, no spontaneous resolution of hypocortisolism 3 weeks after infection | Chua et al. (26) |
| Hypothalamic involvement with ophthalmoparesis or acute ischemic stroke or encephalitis (4 cases) | M. 28 yr, healthy | 14 days | Myocarditis; polyuria, polydipsia, hyponatremia, and low urine osmolarity | Administration of 2 µg of desmopressin with clinical improvement | Sheikh et al (24), Sheikh et al. (25) |
| | F. 44 yr, T2DM | 12 days | Biochemical and dynamic test suggestive for central adrenal insufficiency (with dizziness, nausea, hypotension) and central diabetes insipidus (polyuria, polydipsia); normal pituitary and brain imaging | Hydrocortisone and desmopressin treatment, with clinical resolution | Sheikh et al. (25) |
| | F. 60 yr, healthy; F. 35 yr, history of bulimia | 10–15 days | Diplopia, headache, nerve palsy, or paresthesia and disorientation, at brain imaging hypothalamic alterations at cranial nerve nuclei | One month after infection resolution, diplopia and episodic memory loss persisted in the two patients, respectively. | Pascual-Goñi et al. (27) |
| | M. 73 yr, healthy | 8 days | Acute ischemic stroke with hemiparesis and hypothalamic alterations at brain imaging | Consequences of stroke | Beyrouti et al. (28) |
| | F. 25 yr, healthy | Contextual to the infection | Anosmia, brain imaging suggestive for encephalitis with hypothalamic involvement | One month after infection, resolution of brain imaging and anosmia | Politi et al. (29) |

M, male; F, female; yr, years; TNS, transnasosphenoidal; SIADH, syndrome of inappropriate antidiuretic hormone secretion; T2DM, type 2 diabetes mellitus.
TABLE 2 | Blood exams.

| Blood parameter     | Data of dosage | n.v.     |
|---------------------|----------------|----------|
| Estradiol (ng/L)    | July 2021      | September 2021 | November 2021 |
| <25                 | <25            | <25      | 25-291      |
| FSH (IU/L)          | 3.85           | 6.1      | 5.1        |
| LH (IU/L)           | 0.29           | <1       | <1         |
| PRL (mcg/L)         | 15.87          | 9        | 8          |
| ACTH (pg/mL)        | –              | 29       | 25         |
| Cortisol (mcg/dL)   | –              | 15.9     | 14.5       |
| HGH (mg/mL)         | –              | 0.84     | –          |
| IGF-1 (ng/mL)       | –              | 133      | –          |
| TSH (mIU/L)         | 1.71           | 1.75     | 1.96       |
| FT4 (ng/L)          | 8.92           | 9.1      | 9.3-17     |
| Testosterone (µg/L) | 0.16           | 0.16     | –          |
| Hemoglobin (g/dL)   | 13.6           | –        | –          |
| Creatinine (mg/dL)  | 0.84           | –        | 0.51-0.94  |
| Glycemia (mg/dL)    | 62             | –        | 60-100     |

n.v., normal values; FSH, follicle-stimulating hormone; LH, luteinizing hormone; PRL, prolactin; ACTH, adrenocorticotropic hormone; HGH, human growth hormone; IGF-1, insulin-like growth factor 1; TSH, thyrotropin-stimulating hormone; fT4, free thyroxine.

triiodothyronine) (Table 3). Ten days after the GnRH analogue test, the patient experienced menstrual spotting for a few days only. On November 3, 2021 (Table 2), hypogonadotropic hypogonadism persisted (still characterized by low LH and estradiol and normal FSH values), without resumption of the menstrual cycle. We plan to reevaluate the patient to decide the diagnostic-therapeutic follow-up, based on her interest in bearing children.

DISCUSSION

We described a case of hypothalamic amenorrhea following COVID-19.

Recently, Phelan and colleagues have described that the hypothalamic circuits) (28, 29) and direct damage (Table 3). Ten days after the GnRH analogue test, the patient experienced menstrual spotting for a few days only. On November 3, 2021 (Table 2), hypogonadotropic hypogonadism persisted (still characterized by low LH and estradiol and normal FSH values), without resumption of the menstrual cycle. We plan to reevaluate the patient to decide the diagnostic-therapeutic follow-up, based on her interest in bearing children.

TABLE 3 | TRH test.

| Parameter         | Time (minutes) after stimulation |
|-------------------|----------------------------------|
|                   | 0’ (at infusion) | +20’ | +40’ | +60’ | +90’ | +7 days |
| TSH (mIU/L)       | 2.14               | 13.90 | 14.20 | 16.70 | 16.30 | 2.27    |
| FT4 (ng/L)        | –                  | 8.92  | 9.1   | 9.3-17|
| FT3 (ng/L)        | –                  | –     | –     | 2.3   |

TRH, thyrotropin-stimulating hormone; TSH, thyrotropin-stimulating hormone; n.v., normal values; FT4, free thyroxine; FT3, free triiodothyronine (n.v. 2.0-4.4 ng/l).

TABLE 4 | GnRH analogous test.

| Parameter     | Time (minutes) after stimulation |
|---------------|----------------------------------|
|               | 0’ (at infusion) | +30’ | +60’ | +90’ | +120’ | +240’ | +24 h |
| LH (IU/L)     | <1                | 10.3  | 10.3 | 11.4 | 11.3  | 13.4  | 6.1   |
| FSH (IU/L)    | 4.8               | 15.6  | 18.2 | 22.6 | 24.7  | 34.1  | 21.4  |
| Estradiol (ng/L) | 25                | –     | –    | –    | –     | –     | 55    |

GnRH, gonadotropin-releasing hormone; FSH, follicle-stimulating hormone; LH, luteinizing hormone.
CONCLUSION

We reported an unusual case of a young woman who developed hypothalamic amenorrhea following COVID-19. More cases are necessary to support the finding of hypothalamic amenorrhea as a complication of SARS-CoV-2 infection, also because it is difficult to directly demonstrate the presence of the virus in the hypothalamic tissue in vivo. Therefore, we suggest clinicians focusing greater attention and follow-up on possible existing or delayed endocrine disorders following COVID-19, in particular focusing greater attention and follow-up on possible existing or hypothalamic tissue dysfunction and female infertility. It would be desirable to consider and identify these possible complications and eventually direct the patient toward an adequate diagnostic–therapeutic management for female reproductive health.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article have been made available by the authors, without undue reservation.

REFERENCES

1. Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, et al. Extrapoluminal Manifestations of COVID-19. *Nat Med* (2020) 26(7):1017–32. doi: 10.1038/s41591-020-0968-3
2. Pal R, Banerjee M. COVID-19 and the Endocrine System: Exploring the Unexplored. *J Endocrinol Invest* (2020) 43(7):1027–31. doi: 10.1007/s40618-020-01276-8
3. Marazuela M, Giustina A, Puig-Domingo M. Endocrine and Metabolic Aspects of the COVID-19 Pandemic. *Rev Endocr Metab Disord* (2020) 21(4):495–507. doi: 10.1007/s11154-020-09569-2
4. Musa BM, Srivastava A, Verberne AJM. COVID-19 and Neurological Impairment: Hypothalamic Circuits and Beyond. *Viruses* (2021) 13(3):498. doi: 10.3390/v13030498
5. Frara S, Allora A, Castellino L, di Filippo L, Loli P, Giustina A. COVID-19 and the Pituitary. *Pituitary* (2021) 24(3):465–81. doi: 10.1007/s11120-021-01148-1
6. Chan JL, Gregory KD, Smithson SS, Naqvi M, Mamelak AN. Pituitary Apoplexy Associated With Acute COVID-19 Infection and Pregnancy. *Pituitary* (2020) 23(6):716–20. doi: 10.1007/s11120-020-01080-w
7. Ghosh R, Roy D, Mandal A, Dutta A, Naga D, Benito-León I. A Rare Case of SARS-CoV-2 Infection Associated With Pituitary Apoplexy Without Comorbidities. *J Endocr Soc* (2021) 5(3):bva203. doi: 10.1210/jendso/bva203
8. Bordes SJ, Phang-Lyn S, Najera E, Borghesi-Razavi H, Adada B. Pituitary Apoplexy Attributed to COVID-19 Infection in the Absence of an Underlying Macroadenoma or Other Identifiable Cause. *Cureus* (2021) 13(2):e13315. doi: 10.7759/cureus.13315
9. Santos CDSE, Filho LMDC, Santos CAT, Neill JS, Vale HF, Kurnutala LN. Pituitary Tumor Resection in a Patient With SARS-CoV-2 (COVID-19) Infection. A Case Report and Suggested Airway Management Guidelines. *Braz J Anesthesiol* (2020) 70(2):165–70. doi: 10.1016/j.bjaene.2020.05.003
10. LaRoy M, McGuire M. Pituitary Apoplexy in the Setting of COVID-19 Infection. *Am J Emerg Med* (2021) 47:329.e1–2. doi: 10.1016/j.ajem.2021.02.045
11. Katti V, Ramamurthy LB, Kanakpur S, Shet SD, Dhoot M. Neuro-Ophthalmic Presentation of COVID-19 Disease: A Case Report. *Indian J Ophthalmol* (2021) 69(4):992–4. doi: 10.4103/ijo.IJO_3321_20

ETHICS STATEMENT

Written informed consent was obtained from the patient for the publication of any potentially identifiable images or data included in this article.

AUTHOR CONTRIBUTIONS

PF followed the patient, performed the literature review, wrote the first draft of the paper, and analyzed and critically discussed the results of the case report. VM followed the patient and wrote the first draft of the paper. AD wrote the first draft of the paper and analyzed and critically discussed the results of the case report. IP analyzed and critically discussed the results of the case report. MR analyzed and critically discussed the results of the case report. AF analyzed and critically discussed the results of the case report and the final version of the paper. CC followed the patient, coordinated the study, and analyzed and critically discussed the results of the case report and the final version of the paper. All authors contributed to the article and approved the submitted version.
